scispace - formally typeset
N

Natanael Zarco

Researcher at Mayo Clinic

Publications -  31
Citations -  401

Natanael Zarco is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Subventricular zone & Biology. The author has an hindex of 9, co-authored 24 publications receiving 269 citations. Previous affiliations of Natanael Zarco include CINVESTAV & Universidad de Guanajuato.

Papers
More filters
Journal ArticleDOI

Naringenin prevents experimental liver fibrosis by blocking TGFβ-Smad3 and JNK-Smad3 pathways.

TL;DR: NAR prevents CCl4 induced liver inflammation, necrosis and fibrosis, due to its antioxidant capacity as a free radical inhibitor and by inhibiting the NF-κB, TGF-β- Smad3 and JNK-Smad3 pathways.
Journal ArticleDOI

Caffeine prevents experimental liver fibrosis by blocking the expression of TGF-β.

TL;DR: The results show that caffeine prevents experimental cirrhosis; the mechanisms of action are associated with its antioxidant properties and mainly by its ability to block the elevation of the profibrogenic cytokine transforming growth factor-&bgr;, which may be associated with attenuation of the inflammatory and fibrotic processes.
Journal ArticleDOI

GAS1 induces cell death through an intrinsic apoptotic pathway.

TL;DR: It is determined that the presence of GAS1 also triggers the dephosphorylation of BAD, which, in turn, provokes the release of Cytochrome-c from the mitochondria to the cytosol activating caspase-9, prompting the activity of caspases-3 and resulting in apoptosis of the cells.
Journal ArticleDOI

Hesperidin prevents liver fibrosis in rats by decreasing the expression of nuclear factor-κB, transforming growth factor-β and connective tissue growth factor.

TL;DR: This study demonstrates that hesperidin prevents experimental necrosis and fibrosis and supports earlier findings demonstrating the beneficial effect of hes peridin against liver damage.